Omeros Corporation is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for a range of medical conditions. The company leverages its expertise in pharmacology and drug development to create innovative treatments, particularly in the fields of inflammation, ophthalmology, and central nervous system disorders. Omeros is committed to addressing unmet medical needs through its proprietary drug candidates, which include both standalone therapies and supportive care products designed to enhance patient outcomes. With a strong emphasis on research and clinical development, Omeros aims to bring transformative therapies to market that improve the lives of patients suffering from complex diseases. Read More
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for marketing approval by both the U.S. FDA and the European Medicines Agency.
Investors searching for small cap stocks under $5 are finding opportunities across biotech, AI, mining, energy, and fintech sectors. Below are several low-priced stocks to watch that combine high-growth potential with upcoming catalysts in Q4 2025.
In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a colossal licensing agreement with pharmaceutical titan Novo Nordisk (CPH: NOVO B). The deal, potentially valued at up to $2.1 billion,
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for marketing approval by both the U.S. FDA and the European Medicines Agency.
Omeros Corp (OMER) reports Q2 2025 with narrowed losses, progress on narsoplimab FDA approval, and strategic debt restructuring. Shares rise on regulatory optimism.
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include:
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
D. Boral Capital served as exclusive placement agent for Omeros Corporation (NASDAQ: OMER), i.e., Omeros (the “Company”), in a registered direct offering with Polar Asset Management Partners that closed July 28, 2025. The Company sold 5,365,853 shares of common stock at $4.10 per share, raising approximately $22 million. The price represents a 14% premium to the closing price on the date of the securities purchase agreement, executed July 24, 2025. The offering was conducted under a “shelf” Registration Statement on Form S-3 (File No. 333-268269) and the accompanying prospectus.
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 31, 2025 / On July 24, 2025, Omeros Corporation (Nasdaq:OMER) ("Omeros" or the "Company") entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22,000,000 of its common stock in a registered direct offering (the "Transaction"). The offering of the common stock was made pursuant to a "shelf" Registration Statement on Form S-3 (File No. 333-268269) and the accompanying prospectus. The Transaction closed on July 28, 2025, pursuant to which the Company sold 5,365,853 shares of its common stock at a price of $4.10 per share, which represents a premium of approximately 14% to the closing price of the Company's common stock on the date of the securities purchase agreement.
